JNM

Volume 64 • Number 12 • December 2023

PRESIDENT'S MESSAGE

1843 A Strategic Approach to Advancing Nuclear Medicine and Molecular Imaging
Helen R. Nadel

EDITOR'S PAGE

1845 The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics
Michael S. Hofman

STATE OF THE ART

1848 Ethical Considerations for Artificial Intelligence in Medical Imaging: Data Collection, Development, and Evaluation
Jonathan Herington, Melissa D. McCradden, Kathleen Creel, Ronald Boellaard, Elizabeth C. Jones, Abhinav K. Jha, Arman Rahmim, Peter J.H. Scott, John J. Sunderland, Richard L. Wahl, et al.

HOT TOPICS

1855 ^{61}Cu-Labeled Radiotracers: Alternative or Choice?
Melpomeni Fani and Guillaume P. Nicolas

FOCUS ON MOLECULAR IMAGING

1858 Imaging Agents for PET of Inflammatory Bowel Disease: A Review
Farzaneh Rezazadeh, Aidan P. Kilcline, and Nerissa T. Viola

ONCOLOGY

Clinical

1865 ■ BRIEF COMMUNICATION. Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma
Christina Laschinsky, Sarah Theurer, Thomas Herold, Josefine Rawitzer, Frank Weber, Ken Herrmann, Tim Brandenburg, Dagmar Führer-Sakel, Wolfgang P. Fendler, and Manuel Weber

1869 PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
Qaid Ahmed Shagera, Ioannis Karfis, Paulus Kristanto, Sideris Spyridon, Romain Diamand, Albert Santapau, Alexandre Peltier, Thierry Roumeguère, Patrick Flamen, and Carlos Artigas

1876 ■ BRIEF COMMUNICATION. ChatGPT: Can You Prepare My Patients for [^{18}F]FDG PET/CT and Explain My Reports?
Julian M.M. Rogasch, Giulia Metzger, Martina Preisler, Markus Galler, Felix Thiele, Winfried Brenner, Felix Feldhaus, Christoph Wetz, Holger Amthauer, Christian Furth, et al.

1880 ■ FEATURED CLINICAL INVESTIGATION ARTICLE. First-in-Humans PET Imaging of *KRAS*^{G12C} Mutation Status in Non–Small Cell Lung and Colorectal Cancer Patients Using [^{18}F]PFPMD
Xiang Li, Jiajun Ye, Jingyi Wang, Zhiyong Quan, Guiyu Li, Wenhui Ma, Mingru Zhang, Weidong Yang, Junling Wang, Taoqi Ma, et al.

1889 Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma
Johannes Duell, Andreas K. Buck, Philipp E. Hartrampf, Wiebke Schlötelburg, Simone Schneid, Alexander Weich, Niklas Dreher, Constantin Lapa, Malte Kircher, Takahiro Higuchi, et al.

THERANOSTICS

Clinical

1895 ■ BRIEF COMMUNICATION. Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans
Taymeyah Al-Toubah, Jaime Montilla-Soler, Ghassan El-Haddad, Mintallah Haider, and Jonathan Strosberg

1899 ^{68}Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study
Ling Chen, Shan Zheng, Linying Chen, Sunwang Xu, Kunlin Wu, Lingjun Kong, Jiajie Xue, Xiangjin Chen, Weibing Miao, and Youzhi Zhu

1906 ■ BRIEF COMMUNICATION. Oncologic Staging with ^{68}Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than ^{18}F-FDG PET/CT
Tristan T. Demmert, Kelsey L. Pomykala, Helena Lanzafame, Kim M. Pabst, Katharina Lueckerath, Jens Siveke, Lale Umutlu, Hubertus Hautzel, Rainer Hamacher, Ken Herrmann, et al.

1910 ^{68}Ga-Labeled Fibroblast Activation Protein Inhibitor (^{68}Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the ^{68}Ga-FAPI PET Observational Trial
Lukas Kessler, Nader Hirmas, Kim M. Pabst, Rainer Hamacher, Justin Ferdinandus, Benedikt M. Schaarschmidt, Aleksandar Milosevic, Michael Nader, Lale Umutlu, Waldemar Uhl, et al.

1918 An Intrapatient Dosimetry Comparison of ^{177}Lu-rhPSMA-10.1 and ^{177}Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
Andreas Rinscheid, Alexander Gäble, Georgine Wienand, Christian Pfob, Alexander Dierks, Malte Kircher, Martin Trepel, Dorothea Weckermann, Constantin Lapa, and Ralph A. Bundschuh

1925 ^{177}Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior ^{223}Ra (RALU Study)
Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Wolfgang P. Fendler, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, et al.

1932 ■ INVITED PERSPECTIVE. Sequential and Combination Therapies of $^{223}RaCl_2$ and Prostate-Specific Membrane Antigen Radioligand Therapy
Hossein Jadvar

1934 **Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics**
Andrea Galbiati, Paulina Dorten, Ettore Gilardoni, Florian Gierse, Matilde Bocci, Aureliano Zana, Jacqueline Mock, Michael Claesener, Juela Cufe, Florian Büther, et al.

Basic

1941 **Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α**
Yana Dekempeneer, Sam Massa, Francis Santens, Laurent Navarro, Marion Berdal, Melissa Miranda Lucero, Ana Rita Pombo Antunes, Tony Lahoutte, Jo A. Van Ginderachter, Nick Devoogdt, et al.

1949 **Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with ^{89}Zr or ^{211}At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma**
Tadashi Watabe, Kazuya Kabayama, Sadahiro Naka, Ryuku Yamamoto, Kazuko Kaneda, Satoshi Serada, Kazuhiro Ooe, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, et al.

1956 ■ **FEATURED ARTICLE OF THE MONTH. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy**
Clara Diaz Garcia-Prada, Léna Carmes, Salima Atis, Ali Parach, Alejandro Bertolet, Marta Jarlier, Sophie Poty, Daniel Suarez Garcia, Wook-Geun Shin, Stanislas Du Manoir, et al.

RADIONUCLIDE THERAPY

Basic

1965 **[^{123}I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer**
Chung Ying Chan, Zijun Chen, Florian Guibbal, Gemma Dias, Gianluca Destro, Edward O'Neill, Mathew Veal, Doreen Lau, Michael Mosley, Thomas C. Wilson, et al.

RADIOBIOLOGY/DOSIMETRY

Clinical

1972 **Clinical Characterization of [^{18}F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy**
Cristian C. Constantinescu, Terry Brown, Shining Wang, Wei Yin, Olivier Barret, Danna Jennings, and Johannes Tauscher

NEUROLOGY

Clinical

1980 **[^{18}F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration**
Ganna Blazhenets, David N. Soleimani-Meigooni, Wesley Thomas, Nidhi Mundada, Matthias Brendel, Stephanie Vento, Lawren VandeVrede, Hilary W. Heuer, Peter Ljubenkov, Julio C. Rojas, et al.

PHYSICS AND INSTRUMENTATION

Basic

1990 **Performance Characteristics of a New-Generation Digital Bismuth Germanium Oxide PET/CT System, Omni Legend 32, According to NEMA NU 2-2018 Standards**
Shin Yamagishi, Kenta Miwa, Shun Kamitaki, Kouichi Anraku, Shun Sato, Tensho Yamao, Hitoshi Kubo, Noriaki Miyaji, and Kazuhiro Oguchi

SPECIAL CONTRIBUTION

1998 **One Hundred Years of the Tracer Principle**
Sebastian Hoberück, Klaus Zöphel, Martin G. Pomper, Steven P. Rowe, and Andrei Gafita

ILLUSTRATED POST

2001 **Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma**
Johanna S. Enke, Ralph A. Bundschuh, Georgine Wienand, Nic G. Reitsam, Malte Kircher, Christian H. Pfob, Constantin Lapa, and Alexander Dierks

LETTERS TO THE EDITOR

2002 **Theranostics Is Not Radiotheranostics**
Weijun Wei

2002 ■ **REPLY. Theranostics Is Not Radiotheranostics**
Wolfgang Andreas Weber

DEPARTMENTS

6A **This Month in JNM**